As for the relationships with therapeutic biomarkers, the results of GSE48075 were similar with those from the TCGA-BLCA cohort, confirming the predictive value of MTHFD2 in the efficacy of chemotherapy, radiotherapy, immunotherapy, and targeted therapy (Figures 6C, D). Here, MTHFD2 is linked to bladder transitional cell carcinoma.